Tonix Pharmaceuticals Receives FDA Feedback Supporting Phase 2 Lyme Disease Prevention Study

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that it received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) that support the company's plans for an adaptive Phase 2 field study of TNX-4800, its long-acting anti-OspA monoclonal antibody candidate designed to prevent Lyme disease. This regulatory feedback is a crucial milestone for the development program, as it provides a clear pathway for the clinical evaluation of a potential seasonal immunopreventative.

The planned study is a randomized, placebo-controlled trial expected to enroll approximately 3,300 adults over two Lyme disease seasons. The primary objective is to evaluate the efficacy of TNX-4800 in preventing Lyme disease through six months after dosing. According to the company, manufacturing of the investigational product is on track for delivery to study sites in the first quarter of 2027. This timeline suggests that Tonix is moving efficiently to initiate the trial, which could provide a new option for individuals at risk of Lyme disease.

TNX-4800 is being developed as a seasonal immunopreventative administered as two subcutaneous injections three months apart. This dosing regimen is designed to provide protection throughout the U.S. Lyme disease season, which typically peaks in the summer months. The potential advantage of this approach is that a single course of treatment could offer sustained protection, reducing the burden of frequent dosing and improving adherence.

The significance of this development lies in the substantial unmet medical need for Lyme disease prevention. Currently, there is no vaccine available for humans in the United States, and preventive measures are largely limited to personal protective behaviors and tick control. An effective immunopreventative could significantly reduce the incidence of Lyme disease, which affects hundreds of thousands of people annually in the U.S. alone.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's recently approved flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. The company is also advancing a pipeline of immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

The FDA's feedback is a positive signal that the design of the Phase 2 study is acceptable for regulatory purposes. This reduces some of the uncertainty associated with clinical development and may facilitate a smoother path to later-stage trials. For investors, this news reinforces the potential of Tonix's immunology pipeline and its commitment to addressing infectious diseases with high public health impact.

The company has noted that its product development candidates are investigational new drugs or biologics, and their efficacy and safety have not been established nor have they been approved for any indication. However, the progress of TNX-4800 into a pivotal-stage study could represent a significant advancement in Lyme disease prevention.